Introduction
Prostate cancer (PC) is the most commonly diagnosed cancer and the second leading cause of cancer death in western men after middle age and remained a major research and public health priority. Tumor growth is originally dependent on androgens which exert their effects on prostate cancer cells by activating the androgen receptor (AR), a member of the hormone nuclear receptor superfamily. In the mature prostatic gland, the AR regulates the expression of genes involved in diverse cellular function, including survival and proliferation of the epithelial cells and lipid metabolism ( ). In early stage tumors, therapy based on androgen deprivation is only temporary effective ( 1 ) , and many men develop recurrent androgen-independent prostate cancer, which has a very poor prognosis ( ). In view of this, new 2 3 therapeutic options are wanted.
One of the first identified biochemical hallmark of cancer cells was an alteration in metabolism. Early in the last century, Otto Warburg (1928) observed that tumors have a higher rate of glucose metabolism than normal tissues ( ). Over the past decades, 4 -6 Page / 2 15 accumulating evidence of a metabolic reorganization has emerged from studies on various proliferating cells. Indeed, most tumor cells are characterized by higher rates of glycolysis, lactate production, and biosynthesis of lipids ( ). Cells use two major sources of fatty acids 7 (FA): exogenously derived (dietary) FA and de-novo endogenously synthesized FA. De novo FA synthesis is very active during embryogenesis, whereas most adult normal cells and tissues, even those with high cellular turnover, preferentially use circulating FA for the synthesis of new structural, and signaling lipids. In contrast, it is now well documented that various tumors and their precursor lesions, including prostate cancer, undergo exacerbated endogenous FA biosynthesis irrespective of the levels of extracellular lipids ( , ). The 8 9 increased lipogenesis in cancer is reflected in overexpression and hyperactivity of lipogenic enzymes such as ATP citrate lyase (ACL), acetyl-CoA carboxylase (ACC), or the fatty acid synthase (FAS) ( ). Moreover, studies with chemical inhibitors have revealed that 10 inhibition of FAS activity results in decreased proliferation and increased apoptosis of cancer cells ( ). De novo fatty acid biosynthesis is 11 required for cancer cells to synthesize new membranes, which have a particular lipidic composition that facilitates the formation of lipid rafts for increased signaling of cell growth receptors, such as erbB2 ( ). Lipogenesis also participates, in cancer cells to generate 12 signaling molecules, such as phosphatidyl inositol, phosphatidyl serine, or phosphatidyl choline, which are important factors to activate proliferative and survival pathways. This is consistent with the observation that in most tumor cells examined, the majority of newly synthesized lipids are phospholipids ( , ) . We therefore hypothetized that targeting de novo lipid synthesis might abrogate tumor 13 14 progression.
An important rate-limiting enzyme in lipogenesis is stearoyl CoA desaturase 1 (SCD1), also commonly known as 9-desaturase. Δ SCD1 is a microsomal enzyme that catalyses the committed step in the biosynthesis of the mono-unsaturated fatty acids (MUFA) from saturated fatty acids (SFA), by introducing a cis-double bond to a fatty acyl-CoAs ( ). The preferred substrates are palmitate (16:0) and 15 stearate (18:0), which yeld palmitoleate (16:1n-7) and oleate (18:1n-9) respectively. These represent the major MUFA of membrane phospholipids, triglycerides, wax esters, and cholesterol esters. Of note, most cancer cells contain higher levels of MUFA that tend to partition into detergent-resistant lipid rafts (reviewed in ( )). Since the ratio of monounsaturated to saturated fatty acids (desaturation 16 index) affects phospholipids composition, and alteration in this ratio has been observed in several cancers ( ), our main hypothesis in this 16 study is that targeting SCD1 and associated lipid synthesis in prostate cancer cells might strongly impact on their proliferation and/or survival, and represent a potent new therapeutic strategy to block prostate cancer progression. As a proof of concept, we have characterized in this study the lipid composition and SCD1 expression in human prostate cancer tissue, and analyzed the effects of SCD1 targeting in prostate cancer cells and prostate tumors in mice.
Materials and Methods

Chemicals
All solvents were HPLC grade and were purchased from various suppliers. Methanol, chloroform, hexane, isooctane were purchased from Carlo Erba (val de Reuil, France). Potassium chloride and standards cholesterol esters (CE), triacylglycerides (TAG) and phospholipids (PL), and fatty methyl ester standarts were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France).
Phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)-P ) was purchased from Cayman chemical (Interchim, Montlu on, France). 3 ç BZ36 synthesis 6-4-(2-Bromo-5-methoxy-benzoyl)-piperazin-1-yl -N-phenylpropyl-nicotinamide compound, was previously characterized as a [ ] specific competitive inhibitor of SCD1 with a IC50 of 100nM ( ). We have synthezised it in our laboratory as BZ36 compound, 17
according the method described in the patent. Structure of the molecule is described in Supplemental Figure 1 .
Human prostate tissue samples
Human prostate tissue was collected from consenting patients, after protocol approval by the local ethics committee (CHU Henry Mondor, Creteil, France). Localized prostate cancer specimens from the peripheral zone of the prostate were obtained from men who had radical prostatectomy as treatment for their prostate cancer, gleason 7 (n 10). Non tumoral prostate specimens were obtained from men ≥ = with benign hyperplasia of the prostate (HBP) who had radical prostatectomy (n 10). The patients did not received any hormonal or = chemical treatment before obtaining tissue specimens. Concerning the methods of tissue handling, the cancer specimens were examined on hematein eosin-stained cryosections. As the cancer cells could be admixed with benign epithelial and stromal cells, areas with more than 70 of cancers cells were selected and macro-dissected. For each selected area, ten sections of 50 m thickness (overall 10 mg tissue) % μ were prepared and used for ratios of MUFA to SFA assessment, as well as for transcripts analysis. For the benign prostatic hyperplasia specimens (including admixed benign epithelial and stromal cells), absence of malignant cells was verified on cryosections. The samples were then sectionned and processed as for the cancer specimens.
Cell culture, transient transfections and RNA interference experiments
The benign PNT2 prostate epithelial cell line was obtained from the European Collection of Cell Cultures (ECACC) (Sigma Aldrich).
The androgen-sensitive LNCaP and the androgen-independent C4-2 human prostate carcinoma cell lines were purchased from Viromed Page / 3 15 Laboratory Inc (Minnetonka, MN, USA). Monolayer cell cultures were maintained in a RPMI 1640 media (Invitrogen, Cergy, France) supplemented with 10 fetal calf serum (FCS), 100 U/ml penicillin, 100 g/ml streptomycin, 10mM HEPES and 1.0 mM sodium pyruvate % μ (Invitrogen) at 37 C in 5 CO . Primary MEFs were obtained from embryos at embryonic day 13.5 by standard methods. LNCaP cells, 2 10 C4-2 cells or 5 10 MEFs SV40 in 100 l of a Matrigel solution. For curative experiments, tumors were allowed to × 6 × 5 μ growth until they were measurable with a caliper. In each group, the mice were randomized according to their established tumor volume and given SCD1 inhibitor BZ36 at 80 mg/kg in 100 l of a labrafil-DMA-tween solution (89:10:1) (treated group) or vehicle alone 
RNA isolation, Reverse transcription and quantitative real-time PCR
RNA was extracted with the use of TRI-Reagent (Euromedex, Mundolsheim, France) according to the manufacturers' recommendations. Reverse transcription of total RNA was performed at 37 C using the M-MLV reverse transcriptase (Invitrogen) and°r andom hexanucleotide primers (Promega, Madison, WI), followed by a 15 min inactivation at 70 C. Quantitative PCR was conducted°u sing the primers specific for human SCD1 and SYBR Green Light Cycler Master Mix (Eurofins MWG Operon, Roissy CDG).
Measurement and analysis of gene expression were performed using the ABI Prism 7300 Sequence detection System software (Applied Biosystems), under the following conditions: 2 minutes at 50 C and 10 minutes at 95 C; and then 40 cycles of 15 seconds at 95 C and 1°°°m
inute at 60 C. The relative content of cDNA samples was normalized by substracting the threshold cycle (C ) of the endogenous 18S°t reference gene to the target gene ( C C of target gene C of 18S). Values are expressed as the relative mRNA level of specific gene 
MTT assay
LNCaP, C4-2 or PNT2 cells were seeded in triplicate 24-wells dishes at a density of 2.5 10 cells/well and cells viability was tested 
Flow cytometry analysis of cell cycle and apoptosis
For cell cycle analysis, LNCaP, C4-2 or PNT2 cells were plated at a density of 2.5 10 cells/well in 6-wells dishes and treated with 
Protein extracts and immunoblot analysis
Protein extracts and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), electrotransfer and immunoblotting were performed as previously described ( ). The primary antibodies rabbit anti-AMPK, rabbit anti-phospho AMPK (Thr172), rabbit 18
anti-AKT and rabbit anti-phospho AKT were purchased from Cell signaling Technology (Ozyme, Saint Quentin Yvelines, France). The primary antibody mouse anti-tubulin was purchased from Lab Vision (Thermo Fisher Scientific, Microm France, Francheville, France). 
Fatty acid analysis
Total lipids from human prostate tissues were extracted three times with 5 mL of Folch mixture (chloroform/methanol, 2/1;V/V) and 500 L of water. Aliquots of the lipid extracts were dried under gaseous nitrogen and were dissolved in 100 L of the Folch mixture and μ μ were separated by thin layer chromatography in different lipid subclasses (CE, TAG and PL) using a hexane/ether/acetic acid (70/30/1; V/V) solvent system. To aid visualization, standards of CE, TAG and PL were co-spotted with samples. Spots were identified under UV light after spraying with 2 , 7 -dichlorofluorescein solution in ethanol and comparing with authentic standards. They were scrapped off the ′ ′ plates and were converted to fatty methyl esters by transesterification with 3 mL of methanol/H SO (19/1;V/V) at 90 C for 30 min. The 2 4 °d ifferent solutions were neutralized with a 1 mL of aqueous solution of 10 of K CO and fatty methyl esters were extracted with 5 mL
of hexane. The fatty methyl esters were dried under gaseous nitrogen and were subjected to gas chromatography (GC) and identified by comparison with standards (Sigma). Total lipids from liver tissues and C4-2 tumor xenografts from vehicle-or BZ36-treated animals were extracted three times with folch mixture, converted to fatty methyl esters as previously described, and subjected to gas chromatography (GC) identification. GC was conducted with a Thermo GC fitted with a flame ionization detector. A supelcowax-10 fused silica capillary column (60m 0.32 mm i.d, 0.25 M film thickness) was used and oven temperature was programmed from 50 C to 200 C, increased 20 × μ°°°C per minute, held for 50 min, increased 10 C per min to 220 C, and held for 30 min.°°D
etermination of SCD activity
SCD activity was measured as previously described with some modifications ( ). Briefly, subconfluent LNCaP, C4-2, PNT2 of Ras 19
SV40 MEFs cells grown in 6-wells plate were incubated with BZ36 at 25 M for 2 h in serum and fatty acid-free DMEM media μ supplemented 0.2 BSA. In this environment, the cells are solely dependent on endogenous fatty acid synthesis for production of storage, % structural and signaling lipids. Trace amount of C palmitic acid were then added to the culture (0.5 Ci/well), and cells were incubated stearic and oleic methyl ester acids were run in parallel to the samples. Air-dried plates were scanned on a PhosphorImager and fatty acid spots on TLC were analyzed with PhosphorImager software. SCD activity was expressed as the ratio of palmitoleic on palmitic methyl ester acids and normalized to cellular DNA content.
Measurement of fatty acid synthesis de novo
The inhibitor BZ36 was added overnight at a final concentration of 25 -palmitate or -stearate for 6 h, and total lipids were folch extracted with chloroform/methanol. Labeled lipids were subjected to TLC in hexane/diethyl ether/acetic acid 90:10:1 (V/V), to separate cholesterol ester, triglycerides and phospholipids. Standards were run for each of the lipid classes. After chromatography, labeled lipid classes were quantified by scintillation counting and radioactivity was normalized to DNA content.
PI(3,4,5)P measurement 3 The production of PI(3,4,5)P in LNCaP and C4-2 prostate cancer cells was measured 24 h following exposure to control medium or to 3 medium supplemented with BZ36 at 25 M. The levels of produced PI(3,4,5)P were quantified after cellular lipids extraction using a 
BrDU staining
LNCaP and C4-2 cells grown on cover slips were incubated for 4 hours with BrdU (100 M final) at 24 hours and 48 hours following μ SCD1 knock-down. Cells were then fixed and permeabilized with cold methanol for 10 min at 20 C. After 3 washes with PBS, DNA was −°d enaturized with 4N HCL for 10 min at RT, and cells were incubated with blocking buffer (PBS-1 BSA). BrDU was then detected with % anti-BrDU monoclonal antibody 1:50 (Dako, Carpinteria, CA) for 1 hour at 37 C. After 3 washes with PBS, cells were incubated with an°F ITC-conjugated anti-mouse secondary antibody 1:150 (Jackson Immunoresearch) for 30 min at 37 C, and slides were mounted in°m owiol.
Statistical analysis
Statistical analysis were performed with unpaired Student s t-test. Differences were considered statistically significant at p < 0.05. 
Results
MUFA content and SCD1 expression are increased during prostate cancer progression
As a first approach to target lipid synthesis pathways in cancer cells we measured FA composition during prostate cancer progression.
The ratio of total monounsaturated to saturated FA was significantly increased in CE, TAG and PL lipid fractions in human prostate cancer tissue samples with Gleason score 7 ( ), suggesting the participation of desaturase enzymes. Interestingly, among the analyzed ≥ Figure 1A MUFAs, those produced by a 9-desaturase activity, in majority palmitoleate (16:1n-7) and oleate (18:1n-9), were the most abundant in all Δ Page / 6 15 lipid subclasses (data not shown). Furthermore, the specific desaturation indexes 16:1n-7/16:0 ( ) and 18:1n-9/18:0 ( ) Figure 1B  Figure 1C were increased in human prostate samples, supporting the participation of the 9-desaturase enzyme. Consistent with this observation, Δ stearoyl-CoA ( 9-desaturase) 1 (SCD1) was increased in cancerous, compared to normal human prostates both at mRNA ( ) and Δ Figure 1D protein ( ) levels, as analyzed by QPCR and immunohistochemistry (IHC) studies respectively. SCD1 expression was also Figure 1E increased, as measured by immunofluorescence in the human prostate cancer cell lines LNCaP and C4-2, compared to the non-tumoral PNT2 benign prostate cell line ( ). Figure 1F 
Pharmacological and genetic inhibition of SCD1 activity induces growth arrest of CaP cell lines in vitro
Because MUFA synthesis and SCD1 expression are both increased in prostate cancer, we next evaluated the effects of inhibition of SCD1 activity, measured by the conversion of exogenous C saturated palmitic acid (16:0) substrate to monounsaturated palmitoleic [ 14 ] acid ( synthesized as BZ36, and used in this study (Supplemental Figure 1) . BZ36 compound has been characterized to specifically inhibit the biological activity of stearoyl-coA -9 desaturase, but not -5 desaturase, -6 desaturase or FAS. In all three cell lines tested a marked Δ Δ Δ reduction of the labelled monounsaturated palmitoleic acid was observed in BZ36-treated, compared to control cells ( ). Figure 2A D -Interestingly, basal SCD1 activity was progressively increased from non-tumoral PNT2 to androgen independent C4-2 cell lines ( Figure   ) , further suggesting the implication of SCD1 in prostate cancer progression. Inhibition of SCD1 activity with BZ36 correlated with a 2D dose dependent decrease in cell proliferation of LNCaP, and C4-2 cancer cells, reaching 100 inhibition at the maximal dose used ( % Figure   ) . Flow cytometry analysis further demonstrated the inhibitory effects of BZ36 in CaP cells, showing accumulation of cells in the 2E F -G0/G1 phase of the cell cycle, concomitant with a decrease in the S phase (Supplemental Figure 2) . Strikingly, no effect in proliferation was observed in the non-cancerous PNT2 cell line, even at a maximal dose ( ). Similar to what observed using SCD1 small Figure 2G molecule inhibitors, genetic SCD1 inhibition using siRNA technology blocked SCD1 protein expression ( , and Supplemental Figure ). These results suggested Figure 2I J that, first, SCD1 activity and lipid synthesis is required in prostate cancer cells in order to proliferate. Second, that non-cancer cells do not require de novo lipid synthesis, and therefore normal cells are not sensitive to inhibition of this pathway. And third, that the inhibitory effects of SCD1 inhibitors are mediated by SCD1 since the same effects are observed when SCD1 is depleted from the cells.
To further document the relation between the level of SCD1 expression and the proliferative potential of prostate cancer cells, we analyzed the effect of over-expressing SCD1 in cells. We demonstrate that SCD1 over-expression in LNCaP and C4-2 cells was associated to a 13,7 and 20,5 increase in proliferation, respectively, as assessed by measuring the percentage of BrdU-incorporating proliferative % % cells at 72h following transient transfection with SCD1 cDNA as compared to mock-transfection (Supplemental Figure S.4 ). This rather modest increase in proliferation indicates that endogenous SCD1 expression levels are likely sufficient to drive changes in lipid synthesis required for proliferation of cancer cells.
Inhibition of SCD1 activity decreases de novo fatty acid synthesis in CaP cell lines
The effects of SCD1 in cell proliferation were likely mediated by the participation of this enzyme in the de novo fatty acid synthesis pathways. This was consistent with the observation that C -palmitate incorporation into CE, TAG and PL, which is a measure of de [ 14 ] novo lipid synthesis was respectively inhibited by 39 , 27 Figure 3E observed in PNT2 cells ( ). Figure 3C , and 3F
SCD1 inhibition interferes with major signaling pathways in prostate cancer cells
Lipids are important signaling molecules that actively participate in triggering specific phosphorylation pathways. Since inhibition of SCD1 activity was associated with a significant reduction in de novo lipids synthesis in prostate cancer cells ( ), we expected also Figure 3 a decrease in these pathways. The relative phosphorylation status of several kinases in both LNCaP and C4-2 cells in response to treatment with BZ36 showed similar important changes as compared to control ( and Supplemental Figure 5 ). Relevant for our study Figure 4A ). In contrast to AKT, BZ36 Figure 4C treatment induced a significant increase in phosphorylated AMPK in both LNCaP and C4-2 cells ( ). Interestingly, BZ36
α Figure 4C activated AMPK more efficiently than the classical AMPK activator AICAR ( ). We next investigated the active phosphorylation Figure 4C status of downstream signaling proteins, such as ERK1/2. Immublot analysis revealed decreased phosphorylation of ERK1/2 in both Lipid synthesis and cancer Mol Cancer Ther . Author manuscript Page / 7 15 LNCaP and C4-2 cells following exposure to BZ36, whereas total ERK expression was not changed ( ). Moreover, we found that figure 4D phosphorylation of GSK3 / (S21/S9), which is inhibited by phosphorylation by AKT, was also abrogated by BZ36 treatment in LNCaP α β and C4-2 cells ( ). These results were consistent with the abrogation of, at least AKT signaling in BZ36 treated cells. figure 4D AKT is activated by PI(3,4,5)P , which is the result of PIP2 phosphorylation by PI3K. Since SCD1 inhibition induced a dramatic 3 decrease in de novo synthesis of phospholipids, which are PI(3,4,5)P precursors, we anticipated that BZ36 would have an impact in PIP3 3 concentration in these prostate cancer cells. ELISA test demonstrated that PI(3,4,5)P concentration was strongly decreased by 84 and 3 % 92 respectively in LNCaP and C4-2 BZ36-treated, compared to non-treated cells ( ). These results suggested that inhibition of % Figure 4E AKT activity in these cells was mediated, at least partially by decreased synthesis of PI(3,4,5)P precursors after BZ36 treatment. To 3 further document the implication of PI(3,4,5)P in mediating SCD1 effect, we asked whether addition of external PI(3,4,5)P could rescue 3 3 cells from the effect of SCD1 inhibition on cell proliferation and signaling. As shown in , the percentage of proliferative C4-2 figure 4F cells BZ36 in both LNCaP, and C4-2 cells ( ). This was fully consistent with changes in the expression of genes in the -cat pathway, Figure 4H β including, but not limited to decreased expression of several members of the frizzled family, or decreased cyclin D1, D2, D3, myc, or c-jun expression, or decreased expression of several Wnt family members in C4-2 cells treated with BZ36 ( ). Taken together these Figure 4I results proved that SCD1 inhibition, directly or indirectly results in a strong disruption of major signaling pathways implicated in cell proliferation, migration, and survival.
Inhibition of SCD1 activity inhibit LNCaP and C4-2 tumor growth in vivo
We next evaluated whether reduction of SCD1 activity by BZ36 could inhibit the growth of pre-established PC tumors in mice, a clinically relevant situation. LNCaP and C4-2 cells were injected subcutaneously in male athymic nude mice. Treatment of each individual mouse started when tumor nodules were measurable. In two independent experiments, we observed that treatment of mice with 80 mg/kg of BZ36 5 days of week during 21 days significantly inhibited both androgen-dependent LNCaP ( ) and androgen-insensitive Figure 5B , and E Figure 5C Figure 5F xenografts for the proliferation-associated marker PCNA confirmed the impact of BZ-36 on tumor cell proliferation with an average 50% decrease of PCNA-positive cells in tumors from animals treated with BZ36 at 80mg/kg compared to tumors from control animals. We next investigated whether the reduction of tumor growth following SCD1 inhibition was associated to changes in fatty acids composition in . Analyze of total lipids extracted from both liver and tumor tissues revealed that the specific ratios of 16:1n-7/16:0 and 18:1n-9/18:0 vivo FA were significantly reduced in both tissues in mice receiving BZ36 treatment, as compared to control mice ( ). This indicates Figure 5G that the observed effects of BZ36 treatment on tumor growth are specific to inhibition of SCD1 9-desaturase activity. between control and BZ36-treated animals. Creatinin and urea blood levels were also similar between control and BZ36-treated animals, revealing an intact kidney metabolism (Supplemental Figure 7E ).
Inhibition of SCD-like activities results in p53-independent loss of viability and reduce tumorigenicity of transformed MEFs
To further document the strong antiproliferative effects of SCD inhibitors on Ras-transformed cells we next tested their impact on Mouse embryonic fibroblasts (MEFs) transformed by genetically defined elements or genetic background that cooperate with Ras in transformation. Proliferation index of MEFs fully transformed by activated Ras (HaRasV12) and SV40 Large T was strongly decreased by BZ36 treatment ( ) whereas that of the slowly growing normal MEFs (WT) was only moderately reduced. Similar to prostate Figure 6A cancer cells, inhibition of SCDs activity in these transformed MEFs resulted in decreased lipogenesis as measured by the decrease of C [ 14 ] -palmitoleic to palmitic methyl ester acids ratio ( ). Figure 6B Importantly, the potent antiproliferative effect of BZ36 on cells containing Large T confirmed that SCD inhibition has impact on cells with altered pRB-and p53-pathways, a hallmark of most cancer cells. Consistently, BZ36 also efficiently blocked the proliferation of p53− / MEFs fully transformed by HaRasV12 ( ). Interestingly, these antiproliferative effects of BZ36 were associated with a strong − Figure 6C induction of cell death (annexin V-positive cells) in all transformed cells, including p53 / MEFS transformed by activated Ras, − − suggesting that the end result of SCD inhibition in cancer cells is a p53-independent cell death ( ). Figure 6D To further investigate the effects of BZ36 on transformed Mefs, we next tested its impact on the capacity of these cells to form tumors when injected in nude mice. Two days after their injection with HaRasV12-SV40 Large T transformed Mefs, mice were treated with -BZ36 or with vehicle only. This treatment significantly and reproducibly reduced the size of tumors induced in these animals all along the 12 days of this experiment ( ). Accordingly, PCNA immunostaining on these tumors demonstrated a significant 61 decrease in Figure 6E % the number of proliferative cells (PCNA-positive) in BZ36-treated tumors compared to vehicle-treated tumors ( ). Strikingly, Figure 6F pre-treatment of mice with BZ36, one week prior injection with transformed cells, also reduced tumor formation in these animals. Indeed, five days after cells were grafted, almost all of vehicle treated mice developed tumors, whereas tumors were observed in only 50 of % BZ36 treated mice ( ). Collectively, these data confirmed our observation with LNCaP and C4-2 human cancer cell lines, and Figure 6G demonstrate that inhibition of SCD activity has a potent inhibitory effect on the cell viability and tumorigenicity of p53-deficient and Ras-transformed cells.
Discussion
Many efforts have been directed during the last years towards more efficient ways to ablate pathways implicated in signaling from growth receptors in cancer cells. These new kinase-directed therapies have been of some success in several cancers, whereas still long lists of cancers, including prostate cancer are unfortunately refractory to these treatments. Although dramatic metabolic differences have been described from long time ago between normal and cancer cells, little efforts have been invested in targeting metabolic pathways for the treatment of cancer. We have previously demonstrated a close relationship between metabolic responses and proliferative stimuli ( ). 21 -23 Changes in this coordinated response might lead to abnormal metabolic changes during tumor development and cancer progression. In the present study, we demonstrate that targeting SCD1, a key lipogenic enzyme required for the biosynthesis of MUFA, might be of great benefit for the treatment of prostate cancer.
One important finding in our study is the increase in MUFA/SFA ratio in prostate cancer tissue from patients with gleason 7, ≥ compared to HBP, and in particular the increase of the monounsaturated palmitoleate and oleate, which are the major products of SCD1.
Consistent with this observation, we demonstrate for the first time the overexpression of SCD1 in human prostate cancer tissues as well as androgen-sensitive and androgen-resistant prostate cancer cell lines. We thus have analyzed the effects of SCD1 inhibition in prostate cancer cells and prostate tumor xenografts in mice, and we have dissected the molecular mechanisms underlying these effects. Inhibition of MUFA synthesis through inactivation of SCD1 enzymatic activity results in major changes in complex lipid composition of the cell, decreases cell proliferation, abrogates growth of prostate tumor xenografts in mice and significantly increases tumor-bearing mice survival.
Importantly, we demonstrate that SCD1 inhibition represses proliferation of both androgen-sensitive LNCaP and androgen-resistant C4-2 prostate cancer cells and , suggesting that it may represent a potent target during the progression of prostate cancer toward in vitro in vivo an androgen-independent status. Interestingly, it has been previously noticed that while FAS expression in prostate cancer is initially sensitive to androgens, this sensitivity is lost in parallel with the emergence of the androgen independent-phenotype ( , ) Furthermore, 24 25 the changes in lipid synthesis following SCD1 repression are translated into the inhibition of the AKT pathway, which is certainly one of the major signaling pathways implicated in advanced PC ( ) Indeed, oncogenic signaling converges in the AKT pathway ( ) and 26 -28 29 this pathway functions to promote tumor growth and the emergence of hormone refractory disease ( , ). SCD1 actively participates in 30 31 the generation of phosphatidyl inositols, which are precursors of PI(3,4,5)P , a known AKT activator. Consistent with this role of SCD1 3 we found decreased concentration of PI(3,4,5)P in prostate cancer cells treated with BZ36, concomitant with a decrease in AKT 3 phosphorylation. Furthermore, targeting AKT pathway results in the inhibition of prostate tumors in mice ( ). On the other hand, AKT 27 activation has been shown to be important for triggering the metabolic switch in cancer cells. First, regulating hexokinase (HK) and ACL
Lipid synthesis and cancer
Mol Cancer Ther . Author manuscript Page / 9 15 activity, which results in increased lipid synthesis substrates. Hexokinase accelerates glycolysis, resulting in increased formation of citrate, which is catalyzed to acetyl CoA in the cytoplasm for lipid synthesis ( , ). And second, AKT stimulates the transcriptional activity of 32 33 SREBP, finally resulting in increased mRNA expression of key enzymes for lipid synthesis such as FAS, or SCD1 ( , ). Our results 34 35 strongly suggest that SCD1 inhibition creates a negative loop in which AKT inactivation results, not only in decreased proliferation and apoptosis of cancer cells, but also in decreased lipid synthesis. Inhibition of de novo fatty acid synthesis may also overcome inactivation of PTEN, which is frequently mutated in prostate cancer ( ). Since PTEN inactivates AKT by degrading PI(3,4,5)P , the PTEN 36 3 inactivation found in cancers demonstrate that elevated PI (3, 4, 5) P levels contribute to oncogenesis ( ). Since PTEN is not expressed in 3 
37
prostate cancer LNCaP and C4-2 cells, our study could be also representative of prostate tumors that carry mutations in PTEN ( ). 36
Interestingly, PNT2 cells express functional PTEN protein, and SCD1 inhibitor does almost not affect proliferation of these cells, which suggest that the effects of this treatment are mediated by decreased production of PI(3,4,5)P . This is further supported by our observation 3 that prostate cancer cell proliferation potential and AKT signaling were rescued from the repressive effect of SCD1 inhibitor following addition of external PI(3,4,5)P . 3 AKT also inhibits GSK3 ( ). We found that GSK3 is activated following SCD1 inhibition, likely through AKT pathway β 38 β abrogation ( ). Consistent with this finding are the decrease in -catenin activity ( ), and the general decrease in the Figure 4C β Figure 4F β -catenin growth promoting trancriptional targets ( ). Complementary to this finding is the observed activation of the Figure 4G AMP-activated kinase (AMPK) pathway. It has been previously shown that oncogenic signaling impairs AMPK activation through LKB1 inhibition ( ). Conversely, AMPK activation inhibits prostate cancer cell proliferation ( ), although the precise mechanism whereby 39 40 AMPK activation induces growth arrest in cancer cells is complex. Several pathways are likely implicated, including p53, p21, or p27 ( , 41
). Our results further support that AMPK activation may interfere with cancer cell metabolism, at least in large part, through the AKT 42 pathway. Concerning the energy status of the cell, the AMP/ATP ratio is expected to be low in cancer cells, a condition in which AMPK is inactive. As a result of lipid synthesis inhibition and AKT pathway abrogation, AMPK may become active. Activated AMPK inhibits on its turn the AKT target and activator mTOR, through both TSC1-2 activation ( ) and direct AKT inhibition ( ). In addition, AMPK 43 40 also inhibits lipid synthesis pathways, which are essential for AKT activation ( ). Summarizing, AMPK activation results in a 44 concomitant inhibition of AKT pathway.
Finally we show that cell transformation by oncogenic signaling, such as Ras-mediated tumorigenesis requires intact lipid synthesis pathways, since inhibition of lipogenesis, such as observed when SCD1 inhibitor is used prevents Ras-mediated transformation, and significantly delays Ras-mediated tumorigenesis of primary fibroblastic cells ( ). This finding strongly suggests that oncogenic Figure 6 signaling triggers a metabolic response that directs the cell to particular lipid synthesis pathways that will facilitate cancer cell growth and survival. Interestingly, in addition of modification of growth factor receptor systems in the cellular membrane, and generating signaling lipids, this modification in lipid synthesis modulates, on its turn the activation of Ras, and other oncogenic pathways through protein lipidation, such as N-myristoylation and S-palmitoylation ( ). Strikingly, it was recently reported that some Wnt proteins are modified 45
by palmitoleate, which is the direct product of SCD1 activity, and that this modification is required for secretion and/or signaling activities of secreted signaling proteins, such as the Wingless proteins Wnt-1 and Wnt-3a ( ). This creates a positive feed-back loop that 46
contributes to sustained cancer cell growth and proliferation. Interesting for our study, although Ras mutations are rare in prostate cancer, activation of the Ras pathway is a common feature of this cancer ( , ). Moreover, it has been shown that in PC a cooperative Ras and 47 48 Wnt oncogenic signaling exists ( ). Indeed, our finding that SCD1 activity is required for Ras-mediated tumorigenesis in Mefs may be of 49 great importance for understanding oncogenic signaling in PC and may support further investigations.
Treatment of prostate cancer is a major goal to be achieved, and we believe that SCD1 targeting should be considered as an alternative or complementary treatment of prostate cancer. Perhaps the most important finding in our study is the inhibition of prostate tumor growth, even tumor remission in a mice model of prostate cancer following pharmacological inhibition of SCD1 with the small molecule BZ36.
Consistent with our work, increased expression of SCD1 was found in lung and liver cancers ( , ). 19 50
Figure 1
Monounsaturated fatty acid content and SCD1 expression are increased with prostate cancer progression The global desaturation index, which corresponds to the ratio of total monounsaturated to saturated fatty acids ( ), and the specific A 
Figure 3
Inhibition of SCD1 activity abrogates fatty acid synthesis in CaP cells de novo in vitro C -palmitate incorporation into CE, TAG and PL was measured in LNCaP , C4-2 and PNT2 ( ) cells after exposure to (A C) The delay in tumor apparition following subcutaneously injection of 5x 10 Ras SV40-tranformed MEFs was (G)
